AXSM vs. SMMT, TEVA, ITCI, GMAB, RDY, MRNA, ASND, QGEN, VTRS, and ROIV
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Viatris (VTRS), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.
Axsome Therapeutics vs.
Summit Therapeutics (NASDAQ:SMMT) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
Axsome Therapeutics received 170 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 70.54% of users gave Axsome Therapeutics an outperform vote while only 58.52% of users gave Summit Therapeutics an outperform vote.
In the previous week, Axsome Therapeutics had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 10 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.87 beat Axsome Therapeutics' score of 0.83 indicating that Summit Therapeutics is being referred to more favorably in the media.
Summit Therapeutics has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
Axsome Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. Summit Therapeutics' return on equity of -85.42% beat Axsome Therapeutics' return on equity.
Summit Therapeutics presently has a consensus price target of $35.40, indicating a potential upside of 6.40%. Axsome Therapeutics has a consensus price target of $169.80, indicating a potential upside of 62.88%. Given Axsome Therapeutics' higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Summit Therapeutics.
4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Axsome Therapeutics beats Summit Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AXSM) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy AXSM Stock Free AXSM Stock Alerts